Download the Agenda


Main Conference Day 2

Day 2

Expand All Sessions [+] Collapse All Sessions [-]

9:00 AM Chairman's Recap of Day 1

Cris Kamperschroer , Senior Principal Scientist, Pfizer

 Cris Kamperschroer
Cris Kamperschroer
Senior Principal Scientist
Pfizer

9:10 AM KEYNOTE ADDRESS: Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms

Prof. Gal Markel , Chief Scientist, Ella Institute of Melanoma Sheba Medical Center

•    Hear about the Sheba Medical Centre’s experience with anti-melanoma immunotherapies, specifically with metastatic melanoma, a highly immunogenic tumor
•    Discover how and why the FDA approved Ipilimumab for metastatic melanomas
•    Learn about new immunomodulatory approaches currently in the development pipeline, with a focus on the novel CEACAM1 immune checkpoint
•    This talk combines multi-disciplinary approaches and describes anti-melanoma immunotherapies from molecular, medical, and business angles

Prof. Gal Markel
Prof. Gal Markel
Chief Scientist
Ella Institute of Melanoma Sheba Medical Center

9:50 AM New Ways to Enhance a Sarcoma Patient’s Immune Response Against Cancer to Improve Patient Outcomes

Prof. Seth Pollack , Assistant Member, Fred Hutchinson Cancer Research Center

•    Capitalise on research on the development of novel immunotherapies for patients with advanced sarcoma, particularly Synovial Sarcoma (SS) and Myxoid/ Round Cell Liposarcoma (MRCL)
•    Hear about pioneering methods for isolating and expanding NY-ESO-1–specific T cells from the peripheral blood of sarcoma patients and adoptively transferring these cells back to patients to specifically kill NY-ESO-1 expressing tumor cells, sparing normal tissues
•    Learn about the results of the current clinical trials were specifically designed to reverse the immune evasion mechanisms and enhance clinical efficacy of adoptive, NY-ESO-1 targeting T cell therapy

Prof. Seth Pollack
Prof. Seth Pollack
Assistant Member
Fred Hutchinson Cancer Research Center

10:30 AM Combining Targeted Therapy and Immune Checkpoint Inhibitors in the Treatment of Metastatic Melanoma

Cris Kamperschroer , Senior Principal Scientist, Pfizer

Metastatic melanoma treatment has considerably progressed in
the past five years with the introduction of targeted therapy
(BRAF and MEK inhibitors) and immune checkpoint blockade
(anti-CTLA4, anti-PD-1, and anti-PD-L1). While each treatment
modality has limitations, synergy may exist when targeted
therapy is combined with immunotherapy.
• An overview of the rationale and evidence for the potential
synergy between targeted therapy and immune checkpoint
blockade
• Addressing challenges and directions for future studies
 Cris Kamperschroer
Cris Kamperschroer
Senior Principal Scientist
Pfizer
ImmunGene's interferon-Antibody fusion proteins focus the interferon warhead on tumor cells and on immune cells in the tumor microenvironment, while causing much less systemic activation of the interferon receptor, resulting in drugs much better tolerated and more effective than the unfused interferons currently in use
In this session, discover:
• All the exciting details of the product development
• Why medical oncologists have long believed that considerably better outcomes could be achieved if patients could tolerate higher doses of interferon
• How ImmunGene have overcome this challenge and have been able to introduce into patients higher levels of fused interferon compared with non fused interferon before causing dose-limiting adverse effects

 Michael Gresser
Michael Gresser
CSO
ImmunGene
Choose from four different round table discussions to participate
in, each moderated by a leading industry figure.

Table 1- Validating Predictive and Robust Biomarkers
Table 2- Discovering Novel Immune Checkpoint Pathways
Table 3- Combination Therapies
Table 4- Best Strategies for Market Success

2:10 PM Improving Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Professor Christopher Rudd , Professor of Molecular Immunology, University of Cambridge

• Cytotoxic T lymphocyte–associated antigen-4 (CTLA-4)
blockade can promote antitumor T cell immunity and clinical
responses
• Determine the effects of CTLA-4 blockade on the T cell
repertoire using next-generation deep sequencing to measure
the frequency of individual rearranged T cell receptor
β (TCRβ) genes
• Discover how this treatment can increase TCR diversity as
reflected in the number of unique TCR clonotypes
Professor Christopher Rudd
Professor Christopher Rudd
Professor of Molecular Immunology
University of Cambridge

2:50 PM Unlocking the Potential: The Future of Immune Checkpoint Therapy to Treat Cancer

Grant Risdon , Head of Corporate Development, Agonox

• Immune checkpoint therapy has led to important clinical
advances and provided a new weapon against cancer
• The way forward for this class of novel agents lies in
the ability to understand human immune responses in the
tumor microenvironment
• Discover valuable information regarding the dynamic nature
of the immune response and regulation of additional
pathways that will need to be targeted through combination
therapies to provide survival benefit for greater numbers of
patients
Grant Risdon
Head of Corporate Development
Agonox
• What does the future hold for immune checkpoint therapy?
Is combination therapy the way forward, and if so which combinations will prove the most significant? This expert
led case study will allow those at the forefront of immune
checkpoint modulation development to share their thoughts,
and debate the future of this game changing therapy

5:10 PM Chairman’s Closing Summary and End of Conference

Cris Kamperschroer , Senior Principal Scientist, Pfizer

 Cris Kamperschroer
Cris Kamperschroer
Senior Principal Scientist
Pfizer

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!

IDGA

Become a Pharma IQ Member and receive our weekly newsletter!